Celgene Cancer Drug Makes Regulatory Strides In China, US

Law360, New York (February 11, 2013, 4:23 PM EST) -- Overcoming serious safety concerns, Celgene Corp. on Monday announced that its blood cancer drug Revlimid has won approval in China, a development that came just days after the company said U.S. regulators would expedite their review of expanded use of the medicine.

The entry into China provides an important new market for a drug whose potential customer base is modestly sized, consisting of the portion of 750,000 patients who both have multiple myeloma and have received at least one prior therapy. China's State Food and Drug...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.